



Patented Medicine
Prices
Review Board

Since 1987

PMPRB COMMUNIQUE

OTTAWA, February 24, 2009

The Patented Medicine Prices Review Board approves a Voluntary Compliance Undertaking for the medicine Strattera.

The Board issued a Notice of Hearing pertaining to allegations of Board Staff that Strattera had been, and was being, sold by Eli Lilly Canada Inc. at prices exceeding those indicated by the Board's Excessive Price Guidelines. On February 4, 2009, the Board received a Voluntary Compliance Undertaking ("VCU") which proposed to resolve the issues raised in the Notice of Hearing.

The VCU, agreed to by Eli Lilly and Board Staff, will ensure that the prices of Strattera are not excessive and that alleged excess revenues, in the amount of \$15,326,066.99, are offset.

By Order of the Board, the proceeding into the price of Strattera is hereby concluded.

The Board Order is a public document and is available on the PMPRB Web site, along with the VCU, under Regulatory; Hearings; Strattera, and under Voluntary Compliance Undertakings.

Strattera is a medicine indicated for the treatment of Attention Deficit/Hyperactivity Disorder ("ADHD") in children 6 years of age and over, adolescents and adults.

Reference:
Sylvie Dupont
Secretary of the Board
Tel: (613) 954-8299; Toll-Free: 1 877 861-2350
E-mail: sylvie.dupont@pmprb-cepmb.gc.ca

The mission of the Patented Medicine Prices Review Board (PMPRB) is to protect consumer interests and contribute to Canadian health care by ensuring that prices of patented medicines are not excessive and by analyzing and reporting to Canadians on price trends of all medicines and on research and development conducted by patentees.

Canada